



July 10, 2017

Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Center - WO66-G609  
Silver Spring, MD 20993-0002

Kossan International Sdn. Bhd.  
Cho Fong  
RA Manager  
Wisma Kossan, Lot 782, Jalan Sungai Putus, Off Batu 3 3/34,  
Jalan Kapar,  
Klang, 42100 MY

Re: K170397

Trade/Device Name: Powder Free Nitrile Patient Examination Glove, Blue Colored, Non-Sterile, Polymer Coated, Tested for Use with Chemotherapy Drugs  
Powder Free Nitrile Patient Examination Glove, White Colored, Non-Sterile, Polymer Coated, Tested for Use with Chemotherapy Drugs

Regulation Number: 21 CFR 880.6250

Regulation Name: Patient Examination Glove

Regulatory Class: Class I

Product Code: LZA, LZC

Dated: June 8, 2017

Received: June 12, 2017

Dear Cho Fong:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely,

**Mark S. Fellman -S**

for  
Lori A. Wiggins, MPT, CLT  
Acting Director  
Division of Anesthesiology,  
General Hospital, Respiratory,  
Infection Control, and Dental Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

### Indications for Use

510(k) Number (if known)  
K170397

Device Name

Powder Free Nitrile Patient Examination Glove, Blue Colored, Non-Sterile, Polymer Coated, Tested for Use with Chemotherapy Drugs

Indications for Use (Describe)

A patient examination glove is a disposable device intended for medical purposes that is worn on the examiner's hand to prevent contamination between patient and examiner.

These gloves were tested for use with chemotherapy drugs per ASTM D6978-05 (Reapproved 2013) Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs.

Chemotherapy Drug and Concentration	Minimum Breakthrough Detection Time in Minutes
Carmustine (BCNU) (3.3 mg/ml)	10.2
Cisplatin (1.0 mg/ml)	>240
Cyclophosphamide (Cytoxan) (20.0 mg/ml)	>240
Cytarabine(100 mg/ml)	>240
Dacarbazine (DTIC) (10.0 mg/ml)	>240
Doxorubicin Hydrochloride (2.0 mg/ml)	>240
Etoposide (20.0 mg/ml)	>240
Fluorouracil (50.0 mg/ml)	>240
Ifosfamide (50.0 mg/ml)	>240
Methotrexate (25.0 mg/ml)	>240
Mitomycin C (0.5 mg/ml)	>240
Mitoxantrone (2.0 mg/ml)	>240
Paclitaxel (Taxol) (6.0 mg/ml)	>240
Thiotepa (10.0 mg/ml)	30.4
Vincristine Sulfate (1.0 mg/ml)	>240

Please note that Carmustine (BCNU) and Thiotepa has extremely low permeation times of 10.2 minutes and 30.4 minutes.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

**CONTINUE ON A SEPARATE PAGE IF NEEDED.**

### Indications for Use

510(k) Number (if known)  
K170397

Device Name

Powder Free Nitrile Patient Examination Glove, White Colored, Non-Sterile, Polymer Coated, Tested for Use with Chemotherapy Drugs

Indications for Use (Describe)

A patient examination glove is a disposable device intended for medical purposes that is worn on the examiner's hand to prevent contamination between patient and examiner.

These gloves were tested for use with chemotherapy drugs per ASTM D6978-05 (Reapproved 2013) Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs.

Chemotherapy Drug and Concentration	Minimum Breakthrough Detection Time in Minutes
Carmustine (BCNU) (3.3 mg/ml)	10.1
Cisplatin (1.0 mg/ml)	>240
Cyclophosphamide (Cytosan) (20.0 mg/ml)	>240
Cytarabine(100 mg/ml)	>240
Dacarbazine (DTIC) (10.0 mg/ml)	>240
Doxorubicin Hydrochloride (2.0 mg/ml)	>240
Etoposide (20.0 mg/ml)	>240
Fluorouracil (50.0 mg/ml)	>240
Ifosfamide (50.0 mg/ml)	>240
Methotrexate (25.0 mg/ml)	>240
Mitomycin C (0.5 mg/ml)	>240
Mitoxantrone (2.0 mg/ml)	>240
Paclitaxel (Taxol) (6.0 mg/ml)	>240
Thiotepa (10.0 mg/ml)	30.4
Vincristine Sulfate (1.0 mg/ml)	>240

Please note that Carmustine (BCNU) and Thiotepa has extremely low permeation times of 10.1 minutes and 30.4 minutes.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

**CONTINUE ON A SEPARATE PAGE IF NEEDED.**